November 18, 2020 -- Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
It has been dubbed the "super plant" because the new, multistory 238,000-sq-mt facility will boast 256,000 L of total manufacturing capacity. Once completed, it will be the largest biopharmaceutical manufacturing facility in the world, according to the company.
With this plant, Samsung Biologics anticipates being responsible for a third of the total global bio-contract manufacturing organization capacity, offering a combined sum of 620,000 L from a single site. Plant 4 will feature a modular design, allowing for certain parts of the facility to begin manufacturing by the end of 2022. The plant is expected to be fully operational in 2023.